 |
 |
 |
 |
Ricardo Morillak answered with scoring system of Matutes et. al. Leukaemia
Vol 8, No 10 (October) 1994 pp 1640-1645.
Frederic I. Preffer answered:CD23 is present on all normal circulating B
cells. It is useful indistinguishing chronic lymphocytic leukemias from
centrocytic/mantle zone malignancies (both of which are all CD19+20+5+
light chain monoclonal) in that the CLLs are generally CD23+, the
centrocytics are generally CD23-.
Response from Mary alice Stetler-Stevenson:
We find the use of FMC7 FITC and CD23 PE useful because CD5 is positive in
Mantle cell lymphoma as well and we feel this a major clinical question we
face- A slightly cleaved CLL or a slightly round Mantle cell in leukemic
phase. Since the prognosis is so different, we feel this is an important
distiction. CD23+ FMC7-, CD5+ is CLL; CD23-, FMC7+, CD5+ is mantle cell.
The other combos depend on intensity of expression compared to each other
and that is why I like them together. Why wouldn't someone include CD20 for
CLL? Dim CD 20 is so helpful.
My same thought--both CD19 and CD20 when paired with CD5 create excellent
patterns in B-CLL.
Gerald E. Marti
Flow and Image Cytometry Section
Laboratory of Medical and Molecular Genetics
Division of Cell and Gene Therapies
CBER FDA NIH Bdg 29B Rm 2NN08
8800 Raockville Pike
Bethesda,MD 20892
301-827-0453 (voice)
301-827-0449 (fax)
|
|
|
|